There came out the final ruling that it is reasonable to refuse the registration of a patent of Telmisartan for the purpose of diabetes treatment
There came out the final ruling that it is reasonable to refuse the registration of a patent of Telmisartan for the purpose of diabetes treatment.
Behringer applied for a patent in January 2006, but the Korean Intellectual Property Tribunal refused it and it was not registered. Behringer refused...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
